Latest contributions from Philip Mease

Philip Mease describes the findings from the SELECT-PsA-2 trial of upadacitinib in patients with psoriatic arthritis and an inadequate response to biologic DMARDs (6.18).

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.